Table 1.

Study Characteristics

Study First Author (Ref. #); Year	N	Mean Age (yrs)	Design	Intervention	Control	Outcome
CARAVAGGIO Agnelli et al. (12); 2020	1,155	67	Open-label RCT (non-inferiority)	Apixaban	Dalteparin	Primary efficacy outcome: VTE recurrence. Primary safety outcome: major bleeding
SELECT-D Young et al. (10); 2018	406	67	Open-label RCT (pilot trial)	Rivaroxaban	Dalteparin	Primary outcome: thromboembolic recurrence. Secondary outcome: major bleeding and CRNMB
Hokusai VTE Cancer Roskab et al. (9); 2018	1,046	64	Open-label RCT (non-inferiority)	Edoxaban	Dalteparin	Primary outcome: composite of recurrent VTE or major bleeding
ADAM-VTE McBane et al. (11); 2020	300	64	Open-label RCT (superiority)	Apixaban	Dalteparin	Primary outcome: major bleeding. Secondary outcome: VTE recurrence

ADAM VTE = Apixaban and Dalteparin in Active Malignancy Associated Venous Thromboembolism: The ADAM VTE Trial; CARAVAGGIO = Apixaban for the Treatment of Venous Thromboembolism trial; CRNMB = clinically relevant non-major bleeding; Hokusai VTE Cancer = Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism; RCT = randomized clinical trial; SELECT-D = Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial; VTE = venous thromboembolism.